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Abstract 
This study aimed to develop a drug carrier system consisting of a polymer containing hydroxyapatite 
(HAp) shell and a magnetic core of iron oxide nanoparticles. Doxorubicin and/or curcumin were 
loaded into the carrier via a simple diffusion deposition approach, with encapsulation efficiencies 
(EE) for curcumin and doxorubicin of 93.03 ± 0.3% and 97.37 ± 0.12% respectively. The co-loading 
of curcumin and doxorubicin led to a total EE of 76.02 ± 0.48%. Release studies were carried out at 
pH 7.4 and 5.3, and revealed higher release was at pH 5.3 expressing the potential application in 
tumor microenvironments. Cytotoxicity assays, fluorescence imaging and flow cytometry showed 
the formulations could effectively inhibit the growth of MCF-7 and HEpG2 cancer cells, being more 
potent than the free drug molecules both in dose and time dependent manner.  Additionally, 
hemolysis tests and cytotoxicity evaluations determined the drug-loaded carriers to be non-toxic 
towards non-cancerous cells. These formulations thus have great potential in the development of new 
cancer therapeutics. 






Regardless to the numerous advancements in the field of cancer treatment, the occurrence [1],[2] and 
death due to breast and hepatocellular carcinoma (HCC) are keep on rising over the years[1],[3] 
where breast cancer and HCC would account for 40, 610 deaths in US and 600, 000 deaths 
worldwide respectively[3]. 
For decades, chemotherapy has been the mainstay treatment for both breast and liver cancer [4]. 
Indeed, in HCC when the patient is diagnosed at late stage, chemotherapy becomes the only 
available option [5]. Doxorubicin has been identified as the most effective chemotherapeutic for 
many cancer types including breast cancer and HCC, despite its having many unavoidable serious 
side effects [6], [7]. Adverse effects mainly originate owing to high plasma levels of free 
doxorubicin, due to the use of high doses systemically [8]. Improved targeting is thus required. 
To achieve this goal, many strategies, such as incorporation into a carrier or combining doxorubicin 
synergistically with another compound to reduce the toxicity have been employed [9]. Many 
selective and passive delivery vehicles have been prepared using nanotechnology [9], with the 
PEGylated liposomal formulation of doxorubicin (Doxil®) being the first to receive clinical 
approval. Doxil shows increased circulation times and more rapid uptake into tumor cells than 
standard doxorubicin formulations, thereby reducing the cardiotoxicity, and other side effects [8], 
[10]. 
A range of more advanced liposomal formulations such as those which are temperature sensitive, 
enzyme sensitive, light sensitive or functionalized with a targeting antibody [11] have also been 
fabricated for the purpose of doxorubicin delivery [10]. In addition, alternate systems copolymer 
micelles [12], hydroxyapatite nanoparticles [13],[14], hydrogels[15] and polymer-lipid hybrid 




reduce the toxicity exerted on normal cells their anti-cancer properties are only slightly improved 
[17]. 
Curcumin, a well-known Asian spice is a polyphenolic compound reported to have anti-carcinogenic 
properties, along with many other beneficial effects [9],[18],[19]. Importantly it is much safer as a 
drug with no dose limiting toxicity [20]. The application of curcumin as an anti-cancer agent has 
been limited due to its low aqueous solubility leading to poor bioavailability, short half-life, and 
rapid excretion [19],[21]. As for doxorubicin, these issues have been ameliorated in various studies 
via loading curcumin in a polymer drug carriers, lipid carriers, dendrimers, liposomes, nanogels, 
micelles, microspheres, cyclodextrins, and inorganic nanoparticles [19],[22],[23]. Because curcumin 
can control and induce cell apoptosis, there may be benefits in applying it in combination therapy 
with chemotherapeutics like doxorubicin [24],[25]. 
Hydroxyapatite nanoparticles (HAp) are well known drug delivery vehicles as they offer high drug 
pay loads, pH sensitivity and controlled release of incorporated active ingredients [19],[26]. On the 
otherhand, to reduce off-target effects, the nanoparticles like iron oxide nanoparticles (IONPs) have 
been used as delivery vehicles to achieve magnetic targeting to tumor cells [18]. 
The combination of HAp with IONPs could be beneficial because it could enhance the 
biocompatibility and also the drug loading ability of magnetic nanoparticles which will ultimately 
provide the targeted delivery option [19],[27]. 
However, in our previous studies it has been shown that a strong interaction in between HAp and 
IONPs could be built up, if a polysaccharide like sodium alginate (NaAlg) is used as a linker [28]. 
The use of magnetic HAp particles has received some attention for the treatment of cancer 
[21],[29],[30]. There is no work to date on the use of HAp- NaAlg-IONP composites for the 
treatment of breast or liver cancer. Therefore, in this study we develop a novel drug carrier which 
can perform targeted, pH responsive and sustained delivery of doxorubicin, curcumin or both 




alginate decorated iron oxide nanoparticles, then loaded with the respective drugs and assessed for 
their activity on two different cancer cell lines (MCF-7 and HEpG2). 
2. Experimental  
2.1. Materials and methods 
Curcumin (>98.0%, HPLC), doxorubicin hydrochloride (Dox- HCl, 98.0-102.0% (HPLC)), calcium 
nitrate tetra hydrate (Ca(NO3)2.4H2O, 99%, ACS), diammonium hydrogen phosphate ((NH4)2HPO4, 
> 99.0%), ammonium iron(II) sulfate hexahydrate ((NH4)2Fe(SO4)2.6H2O, 99.0%, ACS), ammonium 
iron(III) sulfate dodecahydrate (NH4Fe(SO4)2.12 H2O, 99.0%, ACS), ethanol (EtOH, > 99.8%, 
HPLC), dichloromethane (CH2Cl2 anhydrous, > 99.8%), alginic acid sodium salt (NaAlg, low 
viscosity), Cetyltrimethyl ammonium bromide (CTAB, > 98%) and TWEEN® 80 (Viscous liquid), 
ammonium hydroxide solution (puriss. p.a., 25% NH3 in H2O) were used as main reagents and 
purchased from Sigma Aldrich, Bangalore, India. Polyethyleneglycol 200 (PEG 200) was purchased 
from Merck Millipore Corporation, Darmstadt, Germany for the preparation of surfactant coated 
IONPs. Snakeskin dialysis tubing (MWCO 3.5 kDa) was purchased from Thermo Fisher, Bangalore, 
India. Ultrapure deionized water was used for all the experiments. 
2.2. Cell lines, animals, and reagents 
The MCF-7 breast carcinoma and HEpG2 hepatocellular carcinoma cell lines were purchased from 
ECACC (Salisbury, UK). MCF-7 cells were cultured in DMEM medium (Gibco, USA) containing 
10% fetal bovine serum (FBS, Gibco, USA), 100 U/mL of penicillin and 100 μg/mL of 
streptomycin, 1% 200 mM L-glutamine (Gibco, USA) and 1% non-essential amino acids 
(NEAA,100x, Gibco, USA) at 37 °C in a humidified 5% CO2 atmosphere. Similarly, HEpG2 cells 
were cultured in complete RPMI 1640 medium at 37 °C in a humidified 5% CO2 atmosphere. The 




USA). The African Green monkey kidney epithelial cell line Vero (ATCC, USA) was grown in 
complete DMEM with passage carried out in every 3-4 days using 0.05% Trypsin EDTA.  
Male Wistar rats of weight 150-200 g were obtained from the rat house of the Zoology Department, 
University of Colombo. The animals were housed in plastic cages under standard conditions 
(temperature 28-31°C; approximately 12 hours’ natural light per day, relative humidity 50-55%). The 
animals were fed with food pellets (Master Feed Ltd, Colombo, Sri Lanka) and provided with 
drinking water ad libitum. Animal experiments were ethically approved by the Institute of Biology of 
Sri Lanka (Registration No: ERC IOBSL140 02 16). 
2.3 Preparation of NaAlg-hydroxyapatite-IONPs (ALG-HI)  
The co-precipitation technique was followed for the synthesis of the drug carrier as reported in our 
previous work [28]. Polyethylene glycol (PEG) coated IONPs were synthesized using 0.1 M iron 
precursor solutions (ammonium iron (II) sulfate hexahydrate ((NH4)2Fe(SO4)2.6H2O), ammonium 
iron (III) sulfate dodecahydrate (NH4Fe(SO4)2.12 H2O) where the obtained IONPs were later 
functionalized with sodium alginate polymer molecules. These alginate functionalized IONPs were 
then added to a 0.25 M Ca(NO3)2 solution maintained at pH 8 under vigorous stirring. The pH was 
adjusted to 9 and a solution of (NH4)2HPO4 was introduced slowly to obtain ALG-HI nanocomposite 
[28]. The resultant black brown suspension was separated, washed and stored at 4°C until further 
use. 
2.4. Drug loading 
The loading of curcumin to ALG-HI was performed via a wet milling approach in accordance with a 
previous report [28]. The obtained yellow brown color suspension (CR-ALG-HI) was separated, 
washed and stored at 4°C for until further use. For the loading of doxorubicin, 33.33 mL of a 50 ppm 
aqueous doxorubicin solution was added immediately to a 0.06g/mL ALG-HI suspension and 
provided with stirring at 120 rpm and at 37°C for 17 hours. The doxorubicin-loaded nanoparticles 




calculated via fluorescence spectroscopy (HORIBA fluorescence spectrophotometer; λexcitation 467 
nm and λemission 589 nm) [31]. In order to load both curcumin and doxorubicin, curcumin was initially 
incorporated to the ALG-HI, magnetically separated, and then the nanoparticles were further 
incubated with 50 ppm doxorubicin solution (DX.CR-ALG-HI). 
2.5. Quantification of the loaded drug content  
The amount of curcumin in the NPs was determined via a simple desorption process[28]. A known 
amount of CUR-ALG was incubated with ethanol under ultrasonic irradiation. Aliquots of the 
released curcumin were taken periodically replacing with an equal amount of fresh ethanol. The 
curcumin content in aliquots was determined spectrophotometrically (GENESYS 10S, ThermoFisher 
Scientific) at 430 nm. 
However, the remaining doxorubicin content was measured via fluorescence spectroscopy 
(HORIBA, Fluorolog, fluorescence spectrophotometer) to calculate the doxorubicin content that has 
been loaded in to the composite nanoparticle. Based on the loaded drug content the drug loading 
capacity and encapsulation efficiency[32] were determined. 
2.6. Characterization of ALG-HI and the drug loaded systems 
The powder X-ray diffraction analysis (PXRD) was performed to determine the crystallographic 
phase of the synthesized ALG-HI. Samples were subjected to Cu kα radiation at λ= 1.5418 Å and the 
measurements were taken in the 2θ range of 5-75 (Bruker D8 Focus X-ray diffractometer, Germany). 
Fourier transform infra-red (FR-IR) spectra were recorded on a Vertex 80 instrument (Bruker, 
Germany). Spectra were collected over the range of 400-4000 cm
-1
 using KBr pellets. Scanning 
electron microscopy (SEM) was performed on a SU 6600 instrument (Hitachi, Japan) operating at 
5.0- 15 kV. Further visualization of the sample was undertaken with the use of transmission electron 
microscope (TEM, JEM-2010, JEOL, Japan) operating at 80 kV.  
Samples were also subjected to X-ray photoelectron spectroscopy (XPS) analysis by NEXUS facility 




equipped with a monochromated Al Kα X-ray source was used with a pass energy of 40 eV and step 
size of 0.1 eV. Spectra were processed using the CasaXPS software (Casa Software Ltd., 
Teignmouth, UK) to identify the possible interactions of the drug molecules with the carrier ALG-
HI. 
2.7. In-vitro release studies  
Release studies were carried out using the dialysis method, similar to the previous work by our group 
[28]. Briefly two PBS buffer solutions at pH 7.4 or 5.3 were prepared and supplemented with 1% 
(w/w) of Tween 80. A known amount of the drug bound nanoparticles were placed in a dialysis bag 
(MWCO of 3500) and immersed in the buffer solutions (20 mL) under gentle stirring at 37°C. At 
specific time intervals, 0.5 ml of the solution was withdrawn and replenished with an equal volume 
of fresh preheated buffer. These aliquots removed were analyzed for curcumin and doxorubicin as 
detailed above. The release study was continued until the solution drug concentration reached an 
equilibrium. All experiments were carried out in triplicate. The following equation (Eq. 1) was used 
to determine the cumulative drug release percentage [33]. 
                            
                                                         
                                            
               
2.8. In-vitro cytotoxicity assessment 
The in vitro cytotoxicity of the formulations against MCF-7 and HEpG2 cells was determined with 
the WST-1 cell viability determination assay [34]. Cells were seeded in 96- well plates (Greiner 
CELLSTAR®, Germany) at a density of 3x10
3
 cells/ well overnight [21],[35]
 
in the appropriate 
media under standard cell culture conditions. They were subsequently treated with a series of 
different concentrations of the nanoparticles and/or drug loaded nanoparticles dispersed in complete 
media for 24, 48 and 72 hours and the subsequently the cell viability was detected [36] using WST-1 
solution (Abcam, UK). The detailed protocol is given in supplementary information.  




Cells were first cultured in 8-well chamber slides (Nunc® Lab-Tek® Chamber Slide™, USA) and 
treated with IC50 concentrations of nanoparticles for 24, 48 and 72 hours. All experiments were 
performed in triplicate. After each incubation the cells were washed with cold PBS, fixed with 3.7% 
paraformaldehyde in PBS (VWR, UK) for 15 minutes at room temperature. The fixed cells were 
washed and treated with 100µg/mL AO/EB (Thermo Fisher Scientific, Life Technologies, 
Singapore) solution for 10 minutes in the dark [37]. Similarly, for Hoechst staining the fixed cells 
were washed with 0.1% Triton X in PBS followed by the addition of 5µg/mL Hoechst (Thermo 
Fisher Scientific, Life Technologies, Singapore) in 0.1% Triton X/PBS and incubated for 15 minutes 
at room temperature in the dark. After each incubation the stained cells were washed with PBS and a 
coverslip placed on the slide using a permanent mounting medium[38].
 
Finally, the samples were 
visualized under a fluorescence microscope (FSX 100, Olympus, Japan). 
2. 10. Flow cytometry 
Apoptosis was quantified by flow cytometry using the Annexin V APC (Biolegend- Cat number- 
640920) and Zombie green (ZG- Biolegend- Cat number - 423111) double staining protocol [39]. 
MCF or HEpG2 cells/well were grown in 24 well plates overnight under standard cell culture 
conditions. On the following day the cells were incubated with the IC50 values of each nanoparticle 
system for another 18 hours. After the incubation they were washed, trypsinized, detached, stained 
and analyzed by flow cytometry. Media alone was used as the negative control. To avoid the spectral 
overlap, single stains of cells with Annexin V and cells with ZG were used as compensation controls 
at each time of the experiment. The expression of Annexin V and ZG were acquired (Guava 
easyCyte 12 HT instrument, Merck, Germany equipped with blue Laser (488 nm), red laser (642nm) 
and violet laser (405nm) and the data were analyzed by FCS express version 4 (denovo software). 
All experiments were undertaken in triplicated. 




Hemolysis (rupture of red blood cells- RBCs) was also used as a measure of cytotoxicity evaluation 
of the nanomaterials[21]. Briefly, rat blood collected into EDTA was centrifuged, rinsed and diluted 
in PBS.  100 µl aliquots of the diluted red blood cells were added to 900 µl of a test solution 
containing different concentrations (0.01- 160.0 µg/mL) of the nanoparticles. The samples were next 
incubated for 2 hours with gentle shaking. RBCs incubated with deionized water and PBS were used 
as the positive and the negative controls, respectively. After incubation the samples were centrifuged 
and the absorbance of the supernatant measured at 541 nm using a UV-visible spectrophotometer 
(ThermoScientificTM GENESYS 10S, India).  All samples were tested in triplicate. The following 
equation was used to obtain the percentage of hemolysis (E.q. 3)[21];  
                          
                            
                                      
                
Where Asample is the absorbance of the blood of the test sample, Anegative control is the absorbance of 
the blood with PBS and Apositive control is the absorbance of the blood with water. 
2.12. Effect of the formulations on rat bone marrow cells 
Myelosuppression is the single most important factor that determines the toxicity in treatment of 
cancer[40]. The detailed description on obtaining rat bone marrow cells is given in supplementary 
information. After several washing steps with RPMI, the primary bone marrow cells obtained from 
sacrificed rats were seeded at a density of 1-9x10
4 
cells/ well in 96 cell well plates in complete RPMI 
medium, and incubated for 3 hours under standard cell culture conditions. These cells were then 
treated with a series of different concentration of nanoparticles for 24 hours[41]. Thereafter, cell 
viability was assessed via the MTT assay protocol[42]. All samples were tested in triplicate in three 
individual experiments. 
2.13. Effect of the formulations on non-cancerous Vero cells 
In addition to the effect on cancerous cells, the effect of these bare nanoparticles and drug loaded 
nanoparticles on a non-cancerous epithelial cell lines such as Vero was also assessed as reported in 




standard cell culture conditions. On the following day they were treated with a series of different 
concentrations of nanoparticles and incubated for 24 hours before cell viability was assessed via the 
WST-1 cell viability assessment assay as specified in section 2.8. 
 
 
2. 14. Statistical analysis 
Data are presented as mean ± SEM. One-way analysis (ANOVA) of variance was used to determine 
statistical significance of the cumulative release rate and cell viability followed by Tukey—Kramer 
post-hoc test analysis of variance. P-values < 0.05 were considered statistically significant. All 
statistical analyses were performed using SPSS version 19 (IBM Corporation, Armonk, NY, USA).  
3. Results and discussion 
3.1. Synthesis and characterization of drug-loaded nanoparticles 
The obtained neat drug carrier was characterized using XRD, FT-IR and SEM analysis and the 
successful synthesis of ALG-HI can be confirmed as data given in supplementary information (Fig. 
S1, Fig. S2 and Fig. S3) which were published in our previous report[28]. 
Fig. 1. displays the FT-IR spectra of the formulations. Fig. 1. a. is the spectra of neat ALG-HI which 
is compared with the drug loaded systems. In neat curcumin (Fig. 1.b.), the appearance of a sharp 
band at 3511 cm
-1
 and a broader peak at 3373 cm
-1
 can be attributed to aliphatic –OH groups and 
phenol –OH groups respectively[19],[35],[44]. When curcumin molecules interacted with the ALG-
HI (CR- ALG-HI) (Fig. 1.c.), there is a clear broadening and the reduction of the –OH stretching 
vibrational bands[45].
 
Furthermore, the appearance of –CH2 stretching vibrational bands of CTAB 
[46]  at 2925 cm
-1
 and 2856 cm
-1
 has masked the appearance of the CH stretch of –O-CH3 of 




Additionally, the 1374 cm
-1
 and 816 cm
-1
 






shifted to 1395 cm
-1
 and 818 cm
-1
 in the curcumin loaded nanoparticles further providing the 
evidence of the interaction of curcumin with the nanoparticles. The FT-IR spectra of both neat 
doxorubicin and DX- ALG-HI are given in Fig. 1. d. and e. Similar observation on the band shifting 
can be made for DX-ALG-HI (Fig. 1.e.). The –OH stretching band of doxorubicin[47] is visible at 
3371 cm
-1
 in DX-ALG-HI , from its position in the neat drug carrier nanoparticle (3141 cm
-1
). The 
presence of bands at 1584 cm
-1
 and 1616 cm
-1
 of neat doxorubicin (Fig. 1.d.) can be attributed to the 
stretching of two carbonyl groups of the anthracyclines [21]. The appearance of an intense band at 
1616 cm
-1
 further confirmed the incorporation of doxorubicin molecules in to the nanoparticle in 
DX-ALG-HI. Moreover, a weak band at 1287 cm
-1 
in the doxorubicin loaded nanoparticle system 
corresponds to the –C-O-C- stretching vibration of doxorubicin[48]. 
When both curcumin and doxorubicin were co-loaded to the ALG-HI (DX. CR-ALG-HI) (Fig.1. f), 
it has become very similar to the CR-ALG-HI. However, the interaction of these drug molecules 





Fig. 1. FT-IR characterization of a) ALG-HI, b) Neat curcumin, c) CR-ALG-HI, d) Neat 
doxorubicin, e) DX-ALG-HI, f) DX.CR-ALG-HI 
As given in Table S1-S4 and Fig. S3-S7., the XPS data clearly indicated that when drug molecules 
interact with the carrier it leads to the shift of the position of the peaks corresponding to Ca, Fe, P, N, 
C and O atoms.  
The morphological observations were taken by SEM and TEM images which are given in Fig. 2. It is 
clear that the nanoparticles are aggregated, and discrete particles are hard to distinguish in the SEM 
images. TEM data show the average size of the neat carrier to be about 13 - 17 nm.  The sizes of the 
CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI are larger at 23.4 ± 5.1 nm, 20.6 ±3.4nm and 
34±5.2 nm respectively. In all the systems, the obtained nanoparticles are well below 50 nm, 
suggesting they will have the ability to be internalized into cells and progress to the nucleus via the 
enhanced permeation retention (EPR) effect[49]. 
  
Fig. 2. SEM and TEM images a) SEM image of neat carrier, b) SEM image of CR-ALG-HI, c) SEM 
image of DX-ALG-HI, d) SEM image of DX.CR-ALG-HI, e) TEM image of neat carrier, f) TEM 
image of CR-ALG-HI, g) TEM image of DX-ALG-HI and h) TEM image of DX.CR- ALG-HI 




The drug loading capacities (DL) and the encapsulation efficiencies (EE) are given in Table S5. It 
could be seen that these systems have different values for those two parameters and both DL% and 
EE% of the co-loaded system are lower than the individual drug loaded systems. 
3.3. Drug release  
The drug release profiles are given in Fig. 3. The neat drug showed a burst of release within a very 
short time independent of pH. However, the release of drugs from the ALG-HI drug carrier showed a 
dependency on pH (higher content at lower pH). In the release patterns of both drugs from their 
carriers, there was an initial burst release within the first 5-6 hours which was then followed 
sustained release pattern over a period of 168 hours. Such a burst release can be attributed to the 
release of the surface adsorbed drug molecules[9]. The subsequent slow release can be attributed to 
favorable interactions between the drug molecules and carrier through electrostatic, van der Waals 
forces and hydrogen bonding[28]. 
The released drug content from each system is tabulated in Table S6. However, in both cases it could 
be seen that the released drug content is higher in singly loaded system than their co-loaded systems.  
 
Fig. 3. Cumulative drug release percentage of each drug from the drug carrier system under pH 7.4 
and 5.3; a) Release of curcumin with and without the drug carrier at two pH environments, b) 
Release of doxorubicin with and without drug carrier at two pH environments Results are presented 




With respect to the curcumin, the doxorubicin cumulative release content is significantly lower 
(P<0.05), which could be due to the favorable interactions that are formed in between the negatively 
charged centers of ALG-HI and the positively charged doxorubicin ions or the Vander Waals  
interactions that are formed between the polysaccharide hexagons in the carrier and the 
doxorubicin[50]. 
The advantage of the drug delivery system prepared in this work are thus clear; it is capable of 
performing sustained and pH sensitive drug release. This may be facilitated by the “open-close gate 
mechanism mediated by CTAB molecules[28] and the gradual dissolution of HAp coating 
material[51]. The system particularly promising for the treatment cancer as the drugs are more 
rapidly released at a lower pH, typical of the cancer micoenvironment [28].
 
3.4. In-vitro cytotoxicity  
The dose response and time response curves for the two cell lines are given in Fig. 4, Fig. 5, Fig. S8 
and Fig. S8. It is clearly observed that the drug loaded ALG-HI have much more profound time 
controlled cell disruption ability than the neat drug molecules. This is expected to be due to the 
controlled release of drug molecules from the nanocarrier, in contrast to the rapid release seen in neat 
drugs. By such a mechanism, the formulations maintain a prolonged anti-proliferative effect which 
would minimize the requirement for repeated dosages.  
Similarly, when considering the IC50 values of each formulation (Table S7) over MCF-7 breast 
cancer cells and HEpG2 hepatocellular carcinoma cells, it is clearly evidenced that these values are 
much lower than the IC50 values of curcumin and doxorubicin alone. The CR-ALG-HI system has 
significantly lower IC50 values (P<0.05) than the neat drug at all three time points. Furthermore, 
compared with the literature, the IC50 values reported for the CR-ALG-HI in our study is 
remarkably low highlighting its potency over both cell types[22],[52],[53].
  
A similar trend has been exerted by the DX- ALG-HI with very low IC50 values. These values are 




ALG-HI the combined system is no more effective with MCF-7 cells than the single-drug systems. 
However, with respect to neat curcumin and doxorubicin, the IC50 values of the co-loaded system 
are much lower. More importantly our systems have much lower IC50 values than have been 
reported in the literature for curcumin/doxorubicin combined treatment of breast and liver 
cancer[9],[22],[25].
 
 With the HEpG2 cells the co-loaded system performs even better than the 
single-drug analogue or the neat drugs, resulting in lower IC50 values. This could be due to the 
synergistic effect[4]
 
created by curcumin molecules over the activity of doxorubicin, and this 
combinational effect is much profound on HEpG2 cells. The increase in glutathione (GSH) levels is 
generally a key factor leading to resistance in chemotherapy or radiotherapy [56]. However, it has 
been found that HEpG2 cells have very high levels of intrinsic GSH[56] rendering for higher IC50 
dosages. Therefore, the co-delivery of both curcumin and doxorubicin via this drug carrier might 
have accounted favorably for the reduction of GSH levels and thereby requiring low IC50 to provide 
the effect. 
Fig. 4. Dose responsive and time response curves of MCF 7 cells treated with ALG-HI, Curcumin 
and CR-ALG-HI a) after 24 hours, b) after 48 hours and c) after 72 hours. Results are presented as 





Fig. 5. Dose responsive and time responsive curves of HEpG2 cells treated with ALG-HI, curcumin 
and CR-ALG-HI a) after 24 hours, b) after 48 hours, c) after 72 hours. Results are presented as mean 
± SD, from three independent experiments each containing three replicates. 
 
3.5. Fluorescence imaging  
Fig. 6,7 and Fig. S10- Fig. S12 depict phase contrast images and fluorescence images of cells that 
have been treated with the nanoparticles for 24, 48 and 72-hours. It is clearly visible that the control 
cells have maintained the fusiform shape while being uniformly stained in green (AO/EB staining) 
and blue (Hoechst staining), showing them to be healthy[57]. However, as shown in Fig. 6. a. b. and 
Fig. S10, when both MCF-7 cells and HEpG2 cells are treated by curcumin, they have started to 
undergo apoptosis, expressing bright yellow to orange nuclei with AO/EB staining and medium to 
bright blue color with Hoechst staining. Further, the cells have shrunk and appeared in  an irregular 
shape[58]. The cell number reduce with time, as cells have undergone death and been removed with 
the washing steps. This effect is much more profound with the CR- ALG-HI treated systems as it has 
led to the appearance of more round shaped cells and bright nuclei due to the chromatin condensation 
and nuclear fragmentation[58]. Most of the cells have lost cell integrity and have not stained well 
with Hoechst[57]. 
Similar observations can be made with doxorubicin and the doxorubicin loaded nanoparticles, as 
given in Fig. 7. and Fig. S11, S12. More specifically it is obvious that the apoptotic effect is much 
stronger with these systems than with curcumin, confirming the potency of doxorubicin and their 
lower IC50 values. The dual drug loaded materials (Fig. S13. a, b) are much effective against HEpG2 





Fig. 6. Phase contrast (PC) and fluorescence images obtained to assess the effect of curcumin and 
CR-ALG-HI on the a) MCF-7 cells, b) HEpG2 cells incubated for 24 hours. Scale bar is 40 µm 
 
Fig. 7. Phase contrast (PC) and fluorescence images obtained to assess the effect of doxorubicin and 
DX-ALG-HI on the a) MCF-7 cells for 24 hours. Scale bar is 40 µm. 
 
3.6. Flow cytometry 
The results of staining to quantify live/apoptotic/late apoptotic and dead cells are given in Fig. 8. and 
Fig. S14. These reveal that, compared to the neat drug molecules, drug loaded ALG-HI show a 
higher percentage of cells lying in the late apoptotic and necrotic or dead stages. This is common to 
all the NP systems. Compared to HEpG2 cells, apoptotic induction in MCF-7 is greater. MCF-7 cells 




with CR-ALG-HI, DX- ALG-HI and with DX.CR- ALG-HI respectively.  Similarly, in HEpG2 cells 
a significant percentage (P<0.05) of cells undergoing apoptosis and necrosis could be seen with cells 
treated with CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI materials (67.01 ± 0.55%, 21.62 ± 
0.67%, 49.55 ± 0.35%) with respect to the control and the neat drug treatment. This has further 
highlighted that the apoptotic induction ability of these systems are far superior than the neat drug 
doxorubicin and therefore could be used as a replacement for the toxic doxorubicin. 
In general, this remarkable apoptosis induction ability of the drug loaded nanoparticles could arise 
due to the higher uptake of the nanoparticles and the diffusion of more drug molecules into the 
nucleus [59],[60]. The histograms of single stains (Cells with Annexin V and Cells with ZG stained 
separately) used as compensation controls are given in Fig. S15. 
 
Fig. 8 Flow cytometric analysis of apoptotic induction of a) MCF-7 and b) HEpG2 cells by drugs and 
drug bound nanoparticles after staining with Annexin V- APC abbreviated as (AN) for ease of 
labelling /Zombie green (ZG). AN-/ZG+, necrotic or debris cells; AN+/ZG+, late apoptotic cells; 




percentage of cells (data are representative of mean ± SD of triplicated of three individual 
experiments) 
3.7. Assessment of hemocompatibility, bone marrow proliferation and effect on non-cancerous 
cells 
As given in Fig. S16. a. and b., low hemolytic percentages well below 1.5%, suggest the 
hemocompatibility of the nanoparticles. These values are very low compared with the reported work 
on these drugs and similar drug loaded nanoparticles[19],[61]. All the drug loaded nanoparticles are 
critically safe to be used for cancer treatment, as recommended by ISO/TR 7406 [61]. 
The effect of the curcumin, doxorubicin, CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI on the cell 
proliferation of rat bone marrow cells (Fig. S17) implied that both ALG-HI nanoparticle and drug 
bound ALG-HI systems maintained a very good cell viability even at high concentrations. Thus, the 
drug loaded nanoparticle systems do not induce adverse effects on bone marrow cells, demonstrating 
their increased biocompatibility which might arise due to the inherent properties of the ALG-HI such 
as HAp, NaAlg and IONPs[42].  
From the cytotoxicity results on non-cancerous Vero cells as depicted in Fig. S18. a, b and c., it is 
clear that there are differences in how cancerous and non-cancerous cells respond to the 
formulations. The viability of the Vero cells is generally high, with the NPs performing significantly 
better than the free drug in this regard. Given that the IC50 values obtained for the drug loaded 
nanoparticles over MCF-7 and HEpG2 cells are very much lower compared to the reported work it 
appears that these formulations are much safer for therapeutic use than the pure drugs. The cytotoxic 
effects caused by our nanoparticles on Vero cells are very low when compared with the reported 
work carried out using carbon nanotubes (CNTs) and Al2O3 nanoparticles [62],[63]. 
4. Conclusions 
A drug carrier comprised of a magnetic core with HAp shell was successfully synthesized and loaded 




observed, and the release of the drugs as was pH sensitive, with faster release in the mildly acidic 
conditions typical of the cancer microenvironment. Extended release over around one week was 
observed. Anti-proliferative studies have proven that CR-ALG-HI, DX-ALG-HI and the dual drug 
loaded ALG-HI are very potent, with lower IC50 values against breast and liver cancer cells than the 
free drug molecules. Fluorescence imaging and flow cytometry reveals that this is due to the greater 
extent of apoptosis induced by the drug loaded nanoparticles. Hemolysis tests, cytotoxic evaluation 
on bone marrow cells and green monkey kidney epithelial cells verified that the nanoparticle systems 
are devoid of adverse side effects, and cause selective toxicity to cancer cells while leaving healthy 
cells unaffacted. The drug loaded nanoparticles reported here could potentially minimize the amount 
of doxorubicin or curcumin required for effective therapeutic action, ensuring thee minimization of 
any possible side effect. 
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